Accelerate Diagnostics (NASDAQ:AXDX) : $1.51 million worth of transactions were on upticks in Accelerate Diagnostics (NASDAQ:AXDX), compared to $0.79 million on downticks. The ratio between the two was 1.91, whereas, the net money flow stood at a healthy $0.72 million on Wednesdays session. The consistent buying on upticks in the stock accounted for $0.68million worth of trades. The total money flow into the stock stood at $0.68 million. The bulls and the bears were in an equilibrium as the stock closed with a loss of -0.7%. The stock was trading at $14.12, with a drop of $0.1 over the previous days close. The stock recorded -5.61% for the week.
In an insider trading activity, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director 10% owner of Accelerate Diagnostics, Inc, Schuler Jack W, had purchased 14,033 shares in a transaction dated on June 14, 2016. The transaction was executed at $13.67 per share with total amount equaling $191,831. Currently the company Insiders own 51.4% of Accelerate Diagnostics shares according to the proxy statements. Institutional Investors own 37.97% of Accelerate Diagnostics shares. During last six month period, the net percent change held by insiders has seen a change of -54.74%.
The company shares have dropped -43.82% from its 1 Year high price. On Jul 23, 2015, the shares registered one year high at $31.29 and the one year low was seen on Feb 9, 2016. The 50-Day Moving Average price is $13.51 and the 200 Day Moving Average price is recorded at $14.53. Accelerate Diagnostics (NASDAQ:AXDX): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $14.34 and $13.65 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $14.75. The buying momentum continued till the end and the stock did not give up its gains. It closed at $14.23, notching a gain of 0.07% for the day. The total traded volume was 367,203 . The stock had closed at $14.22 on the previous day.
Accelerate Diagnostics, Inc. is an in-vitro diagnostics company providing solutions to improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. The Company is focused on reducing the failure rate of initial antibiotic drug therapy by shortening lab turnaround time to approximately five hours, rather than the two to three days required to deliver identification and susceptibility results. It has developed a diagnostic platform, the Accelerate ID/AST System (the ID/AST System), intended for the rapid diagnosis of infectious pathogens. The ID/AST System utilizes genotypic technology to identify (ID) infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. Accelerate Diagnostics UK Limited is a subsidiary of the Company.